Akari Therapeutics Amends S-3, Details Warrants for Resale at Deep Discount
AKTX has more than doubled off its 52-week low of $3.015 on light trading volume (0.1× avg).
Summary
Akari Therapeutics filed an S-3/A detailing the terms for the resale of nearly 6 million ADSs, including warrants exercisable at $3.74 per ADS, which is a deep discount to the current market price. This confirms the mechanics of a highly dilutive capital raise for a company facing a "going concern" warning.
Key Events · Financing and Capital Events · AKTX
-
Resale Registration Details
The filing registers the resale of 5,999,999 American Depositary Shares (ADSs) by selling shareholders, following a previous S-3 filing on July 2, 2026.
-
Deeply Discounted Warrants
A significant portion of these ADSs are issuable upon the exercise of Series H and Series I warrants at an exercise price of $3.74 per ADS, substantially below the current stock price of $14.21.
-
Extreme Potential Dilution
The total ADSs registered for resale represent over 480% of the company's current outstanding shares, indicating extreme potential dilution for existing shareholders.
-
Going Concern Context
This capital raise is critical for the company, which previously reported a "going concern" warning with a cash runway extending only into June 2026.
Analysis · AKTX · Life Sciences
This S-3/A filing provides the specific terms for the resale of nearly 6 million ADSs, including warrants with an exercise price of $3.74 per ADS, significantly below the current market price of $14.21. This registration finalizes the mechanics of a highly dilutive capital raise, which is critical for the company's survival given its recent "going concern" warning and limited cash runway. The potential issuance of these shares represents over 480% dilution to existing shareholders.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 43.4% of the 1019 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.13%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKTX was trading at $14.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.7M. The 52-week trading range was $3.02 to $49.60. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.